TY - JOUR
T1 - Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic
AU - Tanno, Luciana Kase
AU - Demoly, Pascal
AU - Martin, Bryan
AU - Berstein, Jonathan
AU - Morais-Almeida, Mario
AU - Levin, Michael
AU - Fiocchi, Alessandro
AU - Sánchez-Borges, Mario
AU - Caraballo, Luis R.
AU - Wong, Gary
AU - Ortega-Martell, José Antonio
AU - Rouadi, Philip
AU - Yáñez, Anahí
AU - Wang, Liang Lu
AU - Peden, David B.
AU - Chikhladze, Manana
AU - González-Díaz, Sandra N.
AU - Fontaine, Jean François
AU - Sublett, James
AU - Chang, Yoon Seok
AU - Passalacqua, Giovanni
AU - Ansotegui, Ignacio J.
AU - Ebisawa, Motohiro
AU - Senna, Gianenrico
AU - Caminati, Marco
N1 - Funding Information:
The authors acknowledge the unrestricted grants received by Mylan, Novartis; the research grants APITHEM and AllerGos.
Publisher Copyright:
© 2021 The Authors
PY - 2021/2
Y1 - 2021/2
N2 - Background: The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic. Methods: We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context. Results: Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as “I have no data” or “I don't know” to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations. Conclusion: The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems.
AB - Background: The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic. Methods: We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context. Results: Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as “I have no data” or “I don't know” to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations. Conclusion: The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems.
KW - Allergen immunotherapy
KW - Allergy
KW - Asthma
KW - Biological agents
KW - Coronavirus
KW - COVID-19
KW - Inhaled steroids
KW - Prevention
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85102356449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102356449&partnerID=8YFLogxK
U2 - 10.1016/j.waojou.2021.100515
DO - 10.1016/j.waojou.2021.100515
M3 - Article
AN - SCOPUS:85102356449
SN - 1939-4551
VL - 14
JO - World Allergy Organization Journal
JF - World Allergy Organization Journal
IS - 2
M1 - 100515
ER -